Phase 4 Study of Dolutegravir (DTG) in Russian Federation

NCT03314064 | Completed Phase 4 DMC

• 1 other identifier: 205908
• Study Type: interventional
• Target: 43
• Locations: 1 country
• Sites: 11

Brief Summary

DTG 50 milligram (mg) tablet was approved for marketing in Russian Federation; however, DTG is not currently available for subjects at Acquired Immune Deficiency Syndrome (AIDS) Centers as it is not available for order and supply via Federal program. This study is an open-label study which will include subjects, who complete taking DTG in studies ING112276, ING113086, ING114915, ING111762, and those subjects who end participation in study 200304 in which they received either DTG or lopinavir/ritonavir (LPV/RTV). DTG will be supplied at a dose of 50 mg once daily to eligible subjects until the subject stops taking DTG or transitions to commercial supply of DTG when available at AIDS Centers via the Federal program. The objective of this study is to bridge the gap between the closure of ING112276, ING113086, ING114915, ING111762 or end of subject's participation in 200304 and the actual availability of commercial DTG at AIDS Centers via Federal program for human immunodeficiency (HIV)-1-infected adult subjects in Russian Federation. The study will also investigate long-term safety of DTG for subjects continuing DTG in Russian Federation.

Conditions

Infection, Human Immunodeficiency Virus; HIV Infections

Keywords

Phase 4; Russian Federation; dolutegravir; long-term safety; Human Immunodeficiency Virus

Outcome Measures

Primary Outcomes (13)

• Number of subjects with drug related Adverse Events (AEs) and Serious Adverse Events (SAEs)

  Drug related AE is defined as all untoward and unintended responses to an investigational medicinal product related to any dose administered. All AEs will be graded according to Division of AIDS (DAIDS) toxicity scale.

  Up to 7 months approximately

• Number of subjects with abnormal hematology parameters

  Hematology parameters will be evaluated and will be graded according to DAIDS toxicity scale.

  Up to 7 months approximately

• Number of subjects with abnormal clinical chemistry parameters

  Clinical chemistry parameters will be evaluated and will be graded according to DAIDS toxicity scale.

  Up to 7 months approximately

• Number of subjects with abnormal urine parameters

  Urine parameters will be evaluated and will be graded according to DAIDS toxicity scale.

  Up to 7 months approximately

• Number of subjects with abnormal electrocardiogram (ECG)

  The number of subjects with abnormal ECG results will be summarized.

  Up to 7 months approximately

• Number of subjects with abnormal radiological scan

  The number of subjects with abnormal radiological scan will be summarized.

  Up to 7 months approximately

• Number of subjects with abnormal physical examination

  The number of subjects with abnormal physical examination will be summarized

  Up to 7 months approximately

• Number of subjects with abnormal blood pressure

  The number of subjects with abnormal blood pressure will be summarized.

  Up to 7 months approximately

• Number of subjects with abnormal heart rate

  The number of subjects with abnormal heart rate will be summarized.

  Up to 7 months approximately

• Number of subjects with abnormal temperature

  The number of subjects with abnormal body temperature will be summarized.

  Up to 7 months approximately

• Number of subjects with abnormal respiratory rate

  The number of subjects with abnormal respiratory rate will be summarized.

  Up to 7 months approximately

• Number of subjects receiving concomitant medications

  All the concomitant medications that the subject will receive will be evaluated.

  Up to 7 months approximately

• Number of subjects achieving HIV-1 ribonucleic acid (RNA) suppression < 50 copies per milliliter (c/mL)

  Efficacy of DTG will be assessed at routine clinical practice based on the maintenance of HIV-1 RNA suppression at \<50 c/mL.

  Up to 7 months approximately

Study Arms (1)

HIV positive subjects continuing DTG

EXPERIMENTAL

HIV positive subjects who complete taking DTG in studies ING112276, ING113086, ING114915, ING111762 and those subjects who end participation in study 200304 in which they received either DTG or LPV/RTV will be included in this study.

Drug: Dolutegravir 50 mg

Interventions

Dolutegravir 50 mg DRUG

DTG is an integrase inhibitor that has been developed for ART of HIV-infection in combination with other antiretrovirals. DTG will be available as 50 mg tablets to be administered once daily.

HIV positive subjects continuing DTG

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• The subject must complete an End of Study (EOS) visit for the originating protocol ING112276, ING113086, ING114915, ING111762, or be withdrawn from 200304 and attend withdrawal visit prior to transitioning to this study.
• Documented evidence of plasma HIV-1 RNA measurement \<50 c/mL at the EOS visit in ING112276, ING113086, ING114915, ING111762, 200304 (for subjects receiving DTG ) and \<400 c/mL for subjects prior receiving LPV/RTV in 200304.
• Based on medical assessment by the subject's Principal Investigator, the subject continues to derive clinical benefit from treatment with DTG as part of combination antiretroviral therapy (cART) and demonstrates stable virologic success. For subjects, currently receiving LPV/RTV and finishing their participation in 200304, possibility to derive clinical benefit from treatment with DTG is assessed by Principal Investigator following recommendation of Independent Data Monitoring Committee (IDMC).
• Subjects must be capable of giving signed informed consent to participate in this study.

You may not qualify if:

• Subjects not currently enrolled in clinical study ING112276, ING113086, ING114915, ING111762, 200304 are not eligible for this study.
• Subjects for whom confirmed virologic withdrawal criteria were met in ING112276, ING113086, ING114915, ING111762, 200304 are not eligible.
• In addition to the above mentioned criteria, investigator/physician must confirm that the subject has no prohibited clinical condition (other medicines or other health conditions, such as hepatic or renal contra-indications). Further, all women of child bearing potential must be cautioned that DTG is not approved for use in pregnancy, and be advised that birth control measures should be in place while taking DTG. Subjects who were permanently discontinued from DTG in the previous study due to intolerance must not be included in this study.

Sponsors & Collaborators

• ViiV Healthcare: lead

Study Sites (11)

GSK Investigational Site

Kazan', 420061, Russia

Location

GSK Investigational Site

Kemerovo, 650056, Russia

Location

GSK Investigational Site

Krasnodar, 350015, Russia

Location

GSK Investigational Site

Moscow, 105275, Russia

Location

GSK Investigational Site

N.Novgorod, 603005, Russia

Location

GSK Investigational Site

Oryol, 302040, Russia

Location

GSK Investigational Site

Saint Petersburg, 190103, Russia

Location

GSK Investigational Site

Saint Petersburg, 196645, Russia

Location

GSK Investigational Site

Smolensk, 214006, Russia

Location

GSK Investigational Site

Toliyatti, 445846, Russia

Location

GSK Investigational Site

Yekaterinburg, 620149, Russia

Location

MeSH Terms

Conditions

Infections; Acquired Immunodeficiency Syndrome; HIV Infections

Interventions

dolutegravir

Condition Hierarchy (Ancestors)

Blood-Borne Infections; Communicable Diseases; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; RNA Virus Infections; Virus Diseases; Slow Virus Diseases; Genital Diseases; Urogenital Diseases; Immunologic Deficiency Syndromes; Immune System Diseases

Study Officials

• GSK Clinical Trials

  ViiV Healthcare

  STUDY DIRECTOR

• GSK Clinical Trials

  GlaxoSmithKline (for GlaxoSmithKline; Human Genome Sciences Inc., a GSK Company; Sirtris, a GSK Company; Stiefel, a GSK Company; ViiV Healthcare)

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: This is an open label, single group study where the eligible subjects will receive DTG 50 mg once daily.

Study Record Dates

• First Submitted: October 13, 2017
• First Posted: October 19, 2017
• Study Start: December 8, 2016
• Primary Completion: October 1, 2018
• Study Completion: October 1, 2018
• Last Updated: February 4, 2019

Record last verified: 2019-01

Locations

RU (11)